Oral Wegovy cleared

A weight-loss drug that used to come in a pen now comes in a pill. On December 22, 2025, the U.S. Food and Drug Administration approved Wegovy tablets, giving Novo Nordisk the first oral glucagon-like peptide-1 treatment cleared in the United States for chronic weight management. (fda.gov) That matters because Wegovy’s active ingredient, semaglutide, works by copying a gut hormone that helps people feel full, eat less, and lose weight over time. The injected version turned obesity treatment into a mainstream medical category after its 2021 launch, but weekly shots were still a hurdle for many patients. (appliedclinicaltrialsonline.com) The new tablet keeps the same basic drug idea but changes the format from a subcutaneous injection, which means a shot under the skin, to a once-daily pill. For people who avoid needles, that shift is less like getting a new medicine and more like getting a new doorway into a treatment they might actually use. (fda.gov) Glucagon-like peptide-1 medicines are designed to act like one of the body’s own “meal is here” signals. After eating, that signal helps slow stomach emptying and tells the brain that enough food has arrived, which is why these drugs can reduce appetite as well as improve blood sugar control. (wegovy.com) Turning that kind of drug into a pill has been harder than putting it in an injection pen. Proteins and peptide-like medicines have to survive the stomach long enough to be absorbed, which is one reason obesity drugs reached the market as shots before they reached the market as tablets. (appliedclinicaltrialsonline.com) Novo Nordisk’s approval rested on a late-stage study called OASIS 4, which tested oral semaglutide 25 milligrams in adults with obesity or overweight. In the trial’s full-adherence analysis, participants on the pill lost an average of 16.6% of body weight at 64 weeks, compared with 2.7% on placebo. (appliedclinicaltrialsonline.com) The results were not just about the average. About one-third of participants who adhered to treatment lost at least 20% of their body weight, while fewer than 3% of placebo participants reached that mark. (appliedclinicaltrialsonline.com) The company also said the study showed improvements in blood sugar, blood pressure, and other cardiovascular risk factors. More than 70% of participants who started the trial with prediabetes had normal blood glucose levels in a post hoc analysis by the end of treatment. (appliedclinicaltrialsonline.com) The Food and Drug Administration label gives the tablet two main uses in adults. Wegovy tablets are approved, with diet and physical activity, both to reduce excess body weight long term and to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight. (fda.gov) The approval also brings the same major warning carried by other semaglutide products. The prescribing information includes a boxed warning about thyroid C-cell tumors seen in rodents and says the drug is contraindicated for patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. (fda.gov) Novo Nordisk framed the pill as an expansion of a franchise that already includes injectable Wegovy and diabetes drug formulations built around semaglutide. In its announcement, the company called the pill the “next chapter” in its glucagon-like peptide-1 portfolio and said manufacturing was underway in North Carolina ahead of a full U.S. launch in early January 2026. (appliedclinicaltrialsonline.com) The timing matters because the obesity-drug market is shifting from a race over who has the strongest injection to a race over who can make treatment easiest to start and easiest to stay on. A once-daily pill will not replace weekly shots for everyone, but it gives doctors and patients a simpler option in a market where convenience can decide whether a prescription gets filled at all. (abcnews.com, usatoday.com) Oral Wegovy is not a small tweak to a popular drug. It is the moment a blockbuster obesity treatment moved from a needle to a bottle, which is often how a specialist therapy starts to look more like ordinary medicine. (appliedclinicaltrialsonline.com, fda.gov)